Eli Lilly shares rose again Tuesday, their sixth increase in the past seven sessions. The drugmaker's market cap also closed ...

Eli Lilly shares have room to keep going as GLP-1 drugs spread their reach.

Let’s delve into the details of each of the evaluated factors, but first, for a quick background: With a $917 Bil market cap, ...

Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific ...

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish line.

Tuesday, November 18, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft ...

Eli Lilly has received CDSCO approval for donanemab, an Alzheimer's treatment for adults in early symptomatic stages ...

Investing.com -- Eli Lilly and Company (India) Pvt. has received marketing approval from India’s Central Drugs Standard Control Organization for donanemab, a medication used to treat Alzheimer’s ...

Eli Lilly receives CDSCO approval for donanemab, a new Alzheimer's treatment targeting early symptomatic stages of the ...

Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump administration regarding the sale of its GLP-1 medication. In a letter to Lilly ...